UPDATE: Jefferies Raises PT to $40 on Aegerion Pharmaceuticals on Strong Juxtapid Start

Jefferies maintained Aegerion Pharmaceuticals (NASDAQ: AEGR ) with a Buy rating and raised the price target from $29.00 to $40.00. Jefferies commented, "Wider 4Q12 loss of $22M on higher OpEx (vs. our estimate). To date 85 NRx written for Juxtapid (translating into $2M in sales once shipped, ~3-4 months following